Development of a disulfidptosis-related prognostic model for endometrial cancer with potential therapeutic target
View abstract on PubMed
Summary
This summary is machine-generated.A new disulfidptosis prognosis score (disulfidptosis-PSEC) shows promise as a biomarker for endometrial cancer (EC). This model accurately predicts patient survival and identifies potential therapeutic targets.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Endometrial cancer (EC) requires novel prognostic biomarkers.
- Disulfidptosis, a newly identified cell death pathway, plays a significant role in cancer progression.
- Existing disulfidptosis-related gene models for EC are limited.
Purpose Of The Study
- To develop and validate a disulfidptosis-related gene prognostic model for endometrial cancer.
- To assess the model's predictive accuracy for overall survival (OS) and disease-free survival (DFS).
- To explore cellular, molecular, and therapeutic implications of the risk groups.
Main Methods
- Constructed the disulfidptosis prognosis score of EC (disulfidptosis-PSEC) using differentially expressed genes from TCGA RNA data (544 EC patients).
- Evaluated model performance using time-dependent ROC analysis and hazard ratios (HR).
- Analyzed cellular/molecular profiles and inferred drug targets for different risk groups.
Main Results
- Disulfidptosis-PSEC demonstrated significant prognostic value for OS and DFS (5-year AUCs 0.71 and 0.69).
- Low-risk group showed significantly better survival (HRs 0.38 for OS, 0.46 for DFS).
- Model was independent of TCGA subtype; low-risk group exhibited increased immune infiltration and fewer mutations, with identified drug targets including serotonin receptor.
Conclusions
- Disulfidptosis-PSEC serves as a robust prognostic biomarker for endometrial cancer.
- The model offers insights into targetable biological processes and potential therapeutic strategies.
- This approach aids in personalized treatment strategies for EC patients.

